TSHA Stock Forecast & Price Target

Taysha Gene Therapies is a promising biotechnology company focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, including Rett syndrome. The company has strong potential for success, with the FDA granting alignment for its ASPIRE safety trial, which is actively enrolling and expected to support a broad ≥2 years label. While potential competition in the space and the need for additional financing may present risks, a DCF with a WACC of 12.6% and perpetuity growth of 2.0% has led to a price target of $12, which reflects a probability-adjusted modeling of key franchises.

Taysha Gene Therapies is a clinical-stage biotechnology company that is developing AAV-based gene therapies for rare monogenic diseases of the central nervous system. While the company has made progress in its clinical programs, the lack of approved gene therapies in the market and potential delays in the regulatory process could negatively impact investor sentiment. Additionally, the complex and difficult manufacturing process for AAV-based gene therapies could also lead to potential delays in development and commercialization. There is also a risk of competition in the market, potentially limiting the commercial potential of Taysha's products. Further, the company may need to raise additional capital before achieving profitability, which could result in share dilution for investors. Overall, these factors contribute to a negative outlook on Taysha Gene Therapies' stock.